Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940150 | 1.00 | EGFR (0.47) | EGFRKMT2ACYP1A2ENPP1ALDH1A1 | |
| SCHEMBL28926201 | 0.79 | EGFR (0.47) | EGFRKMT2ACYP1A2ENPP1MAPK7 | |
| SCHEMBL30940152 | 0.79 | EGFR (0.47) | EGFRKMT2ACYP1A2ENPP1MAPK7 | |
| SCHEMBL2797267 | 0.76 | ADORA1 (0.40) | KMT2AALDH1A1HPGDPDE4APDE4B | |
| SCHEMBL30940151 | 0.75 | KMT2A (0.53) | EGFRKMT2ACYP1A2ALDH1A1LMNA | |
| SCHEMBL30442027 | 0.75 | CYP1A2 (0.45) | EGFRKMT2ACYP1A2ENPP1ALDH1A1 | |
| SCHEMBL20771342 | 0.75 | CYP1A2 (0.45) | EGFRKMT2ACYP1A2ENPP1ALDH1A1 | |
| SCHEMBL6833680 | 0.75 | PDE4A (0.42) | KMT2AALDH1A1LMNASMN1; SMN2PDE4A | |
| SCHEMBL6836394 | 0.72 | EGFR (0.43) | EGFRALDH1A1LMNASMN1; SMN2PDE4A | |
| SCHEMBL23386760 | 0.71 | ENPP1 (0.36) | KMT2ACYP1A2ENPP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099494-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4467552-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-118339172-A | Phosphonic acid compounds and prodrugs thereof, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117980293-A | Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof | 上海海和药物研究开发股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023138637-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | 上海海和药物研究开发股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023036289-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-03-16 | — | — | WO | disclosed |
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| WO-2019170543-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | MAPK15, MAPKAPK5, MAP3K5 | EGFR 316/4885KMT2A 3546/4885CYP1A2 1992/4885 |
| US-20250099494-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | ENPP1, ENPP3, PPA1 | EGFR 1844/4885KMT2A 3466/4885CYP1A2 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.